- Home
- AGEN vs ABOS Comparison
AGEN vs ABOS Comparison
Compare AGEN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- ABOS
- Stock Information
- Founded
- AGEN 1994
- ABOS 1996
- Country
- AGEN United States
- ABOS United States
- Employees
- AGEN N/A
- ABOS N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- ABOS Health Care
- Exchange
- AGEN Nasdaq
- ABOS Nasdaq
- Market Cap
- AGEN 96.2M
- ABOS 99.1M
- IPO Year
- AGEN 2000
- ABOS 2021
- Fundamental
- Price
- AGEN $3.83
- ABOS $1.63
- Analyst Decision
- AGEN Buy
- ABOS Strong Buy
- Analyst Count
- AGEN 3
- ABOS 3
- Target Price
- AGEN $10.50
- ABOS $9.33
- AVG Volume (30 Days)
- AGEN 399.9K
- ABOS 416.5K
- Earning Date
- AGEN 03-13-2025
- ABOS 11-12-2024
- Dividend Yield
- AGEN N/A
- ABOS N/A
- EPS Growth
- AGEN N/A
- ABOS N/A
- EPS
- AGEN N/A
- ABOS N/A
- Revenue
- AGEN $160,427,000.00
- ABOS N/A
- Revenue This Year
- AGEN N/A
- ABOS N/A
- Revenue Next Year
- AGEN $36.13
- ABOS N/A
- P/E Ratio
- AGEN N/A
- ABOS N/A
- Revenue Growth
- AGEN 59.00
- ABOS N/A
- 52 Week Low
- AGEN $2.50
- ABOS $1.53
- 52 Week High
- AGEN $19.69
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- AGEN 65.58
- ABOS 38.36
- Support Level
- AGEN $3.08
- ABOS $1.53
- Resistance Level
- AGEN $3.29
- ABOS $1.75
- Average True Range (ATR)
- AGEN 0.27
- ABOS 0.13
- MACD
- AGEN 0.08
- ABOS 0.01
- Stochastic Oscillator
- AGEN 94.84
- ABOS 23.81
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.